Thyroid carcinoma (TC), as the most prevalent endocrine malignancy, is mainly originated from thyroid follicular epithelial cells, encouraging the rise of papillary, follicular and poorly differentiated or anaplastic entities whereas about 5% TC from parathyroid follicular thyroid cells. 1 Anaplastic thyroid carcinoma (ATC) is rare but extremely aggressive with a high mortality rate while differentiated TC is relatively common and indolent. 2 Various therapies such as surgery, radiotherapy and chemotherapy have been implied in the use of TC, but with limitations in drug resistance, postoperative complications and side effects or unmet efficacy. 3 Facing to the obstacles in treating TC, the requirement for therapeutic agents targeting TC positions a priority.The co-expression network of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) has been extensively discussed in TC.Exactly, it is recorded that miR-146b-5p negatively regulates lncRNA MALAT1 to function in papillary TC (PTC) cell invasion and proliferation. 4 Also, by co-working with miR-206 and miR-599, lncRNA